REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
Active, not recruiting · NCT05902533 · Registry updated 2025-12-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation | Anal Cancer, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, anus disorder, anus neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2025-12-18 | NCT05902533 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Cincinnati | 87 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ohio State University Medical Center | Columbus | United States | 33 |
| University of Cincinnati Medical Center | Cincinnati | United States | 83 |
| University of Vermont | Burlington | United States | 9 |